Key result
Peptidyl and non-peptidyl Kv1.3 channel blockers have emerged as a general strategy for immunosuppression, as detailed in patent filings from 1996 to 2000.
This review summarizes early patent activity (1996-2000) for Kv1.3 channel blockers as a novel strategy for immunosuppression.
Early Kv1.3 patents flag immunosuppression potential; leaves open clinical translation and modern trial validation.
Blockers of the Kv1.3 channel, a voltage-gated K+ channel found in human T-cells, have recently been recognised as a general strategy for immunosuppression. These blockers are divided into two classes – peptidyl and non-peptidyl Kv1.3 channel blockers. This article covers the patents filed for Kv1.3 channel blockers dating from 1996 to the first quarter of 2000.
No takes yet. Share an insight, caveat, or question.
Lew et al. (2000) studied this question. Peptidyl and non-peptidyl Kv1.3 channel blockers have emerged as a general strategy for immunosuppression, as detailed in patent filings from 1996 to 2000.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: